ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Geropharm and Valenta Pharm JSC side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

GeropharmValenta Pharm JSC
studies on the registry2340
open to participants now018
phase 3 studies under way12
reach primary completion within a year07
programswith a study of their own in two years19

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGeropharmValenta Pharm JSC
Phase 100%44%
Phase 200%

Valenta Pharm JSC: 2 of its 9 programs at phase 2

  1. Gramicidinphase 2
  2. Ingavirin Forte, 90 mg + 5 mg, Capsulesphase 2
22%
Phase 3

Geropharm: 1 of its 1 programs at phase 3

  1. insulin glulisinephase 3
100%

Valenta Pharm JSC: 1 of its 9 programs at phase 3

  1. 4-MUSTphase 3
11%
Approved, new studies00%

Valenta Pharm JSC: 2 of its 9 programs at approved, new studies

  1. pentanedioic acid imidazolyl ethanamideapproved, new study
  2. GB-115approved, new study
22%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Geropharm0 readouts · 0 phase 3············
Valenta Pharm JSC4 readouts · 0 phase 3·

Valenta Pharm JSC, Dec ’26: 4 programs whose next study reaches primary completion

  1. Cetylpyridiniumphase 1 · Dec 1 · NCT06859281
  2. 4-MUSTphase 3 · Dec 31 · NCT06842966
  3. Gramicidinphase 2 · Dec 31 · NCT06843018
  4. Trimedat®phase 1 · Dec 31 · NCT07421011
··········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Geropharm

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Valenta Pharm JSC

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.

ConditionGeropharmValenta Pharm JSC
Diabetes Mellitus, Type 2both · compare here

Geropharm in Diabetes Mellitus, Type 2: 1 program

  1. insulin glulisinephase 3

Their studies: Geropharm’s studies of Diabetes Mellitus, Type 2 in search

Valenta Pharm JSC in Diabetes Mellitus, Type 2: 1 program

  1. Cetylpyridiniumphase 1

Their studies: Valenta Pharm JSC’s studies of Diabetes Mellitus, Type 2 in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Geropharm 1 of 1 · Valenta Pharm JSC 1 of 9 programs (1 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.